LCZ696 is a new drug under development by Novartis. The drug is believed to be a significant improvement over existing drugs; it not only inhibits hormones that constrict blood vessels like existing medications but also boosts the production of beneficial hormones. The clinical trials showed a 20% reduction in death from cardiovascular causes, a 16% reduction in death from any cause and also reduced hospitalization for heart failure by 1/5th among participants.
The highly successful results in the clinical trials led the researchers to end the trial at an early stage after 27 months. Novartis plans to apply for a license in early 2015, which means that the drug will be available in markets the same year provided the license is granted.